TRUL:CA:CNSX-Trulieve Cannabis Corp (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 16.06

Change

-0.07 (-0.43)%

Market Cap

USD 2.92B

Volume

0.07M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Trulieve Cannabis Corp., together with its subsidiaries, operates as a cannabis retailer. The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through home delivery. It sells flowers, edibles, vapes, creams, balms, salves, lotions, vaporizers, batteries, cartridge, concentrates, topicals, capsules, synringes, tinctures, and accessories under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli, Trekkers, and Roll One brands. The company operates dispensaries in Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania. It also operates cultivation and processing facilities in Arizona, Colorado, Florida, Georgia, Maryland, Pennsylvania, and West Virginia. The company was formerly known as Schyan Exploration Inc./Exploration Schyan Inc. and changed its name to Trulieve Cannabis Corp. in September 2018. Trulieve Cannabis Corp. was incorporated in 1940 and is headquartered in Quincy, Florida.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-02 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
GTII:CA Green Thumb Industries Inc

-0.04 (-0.25%)

USD 3.28B
CL:CA Cresco Labs Inc

-0.02 (-0.90%)

USD 0.77B
AYR-A:CA Ayr Wellness Inc

+0.01 (+0.41%)

USD 0.28B
PLTH:CA Planet 13 Holdings Inc

N/A

USD 0.26B
GRIN:CA Grown Rogue International Inc

+0.03 (+3.23%)

USD 0.21B
AAWH-U:CA Ascend Wellness Holdings Inc.

-0.02 (-2.50%)

USD 0.17B
JUSH:CA Jushi Holdings Inc

+0.06 (+9.23%)

USD 0.13B
IAN:CA iAnthus Capital Holdings Inc

+0.01 (+50.00%)

USD 0.10B
MRMD:CA MariMed Inc.

N/A

USD 0.09B
FFNT:CA 4Front Ventures Corp

N/A

USD 0.06B

ETFs Containing TRUL:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 134.45% 84% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 134.45% 84% B 84% B
Trailing 12 Months  
Capital Gain 214.90% 93% A 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 214.90% 93% A 88% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -8.73% N/A N/A 54% F
Dividend Return -8.73% N/A N/A 54% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 71.77% N/A N/A 35% F
Risk Adjusted Return -12.16% N/A N/A 56% F
Market Capitalization 2.92B 98% N/A 100% F

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector